Speaker(s): 

Stephanie Kramer, Resident II, Pharmacy, Geisinger Staff - has nothing to disclose  

Moderator(s): 

Sarah Hale, Pharm.D., BCPPS. Director of Pharmacy, Geisinger-has nothing to disclose 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Recall the pathophysiology and treatment of status epilepticus
• Assess patient eligibility for therapy based on the design of the Ket-Mid study
• Recognize the strengths and weaknesses of the study to extrapolate clinical take-aways

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Sarah F. Hale, PharmD, Brain Simpkins, PharmD, Jessica Milheim, CPhT, and Tiffany Tang, PharmD have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None